The therapeutic application of the CCR4 inhibitor (tumor implantation: n = 20, n = 5 died in <14 days; long-term survivors: n = 2) gave a median survival of 44 days, which was not significantly improved (p = 0.066) compared to control animals (tumor implantation n = 20, n = 8 died in <14 days; long-term survivors n = 0) (median survival: 41 days) (Figure 2c). This evidence concerns the gene CCR4 and neoplasm.